A Study of Pemafibrate in Patients With Nonalcoholic Fatty Liver Disease (NAFLD)

PHASE2CompletedINTERVENTIONAL
Enrollment

118

Participants

Timeline

Start Date

December 27, 2017

Primary Completion Date

April 3, 2019

Study Completion Date

June 30, 2020

Conditions
Non-Alcoholic Fatty Liver Disease
Interventions
DRUG

K-877

0.2mg tablet

DRUG

Placebo

K-877 matching placebo tablet

Trial Locations (16)

030-8553

Aomori Prefectural Central Hospital, Aomori, Aomori

078-8510

Asahikawa Medical University, Asahikawa, Hokkaido

104-0031

Fukuwa Clinic, Chuo-ku, Tokyo

814-0180

Fukuoka University Hospital, Fukuoka, Fukuoka

430-8558

SeireiHamamatsu General Hospital, Hamamatsu, Shizuoka

431-3192

Hamamatsu University Hospital, Hamamatsu, Shizuoka

438-8550

Iwata City Hospital, Iwata, Shizuoka

436-8555

Chutoen General Medical Center, Kakegawa, Shizuoka

830-0011

Kurume University Hospital, Kurume, Fukuoka

951-8520

Niigata University Medical & Dental Hospital, Niigata, Niigata

503-8502

Ogaki Municipal Hospital, Ogaki, Gifu

520-2192

Shiga University of Medical Science Hospital, Otsu, Shiga

060-8648

Hokkaido University Hospital, Sapporo, Hokkaido

990-9585

Yamagata University Hospital, Yamagata, Yamagata

230-8765

Saiseikai Yokohamashi Tobu Hospital, Yokohama, Kanagawa

236-0004

Yokohama City University Hospital, Yokohama, Kanagawa

All Listed Sponsors
lead

Kowa Company, Ltd.

INDUSTRY

NCT03350165 - A Study of Pemafibrate in Patients With Nonalcoholic Fatty Liver Disease (NAFLD) | Biotech Hunter | Biotech Hunter